News Lynparza boosts long-term survival in early breast cancer A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.
News Merck signs €1.4bn cancer alliance with China’s Hengrui Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an
News AZ aims at Pfizer, GSK with potential new PARP cancer drug AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer.
News Tesaro and Roche to combine drugs in bladder cancer trials Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
News Rubraca outshines rivals in ovarian cancer maintenance thera... Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
News Amid sector disruption, biotech must focus on 'fundamentals'... The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face